Cresset Announces Excellent 2012 Sales Figures and Growth
News Jan 22, 2013
Dr Robert Scoffin, CEO of Cresset, says, “We are delighted to announce robust growth through 2012 in both our software and services divisions. We have invested in the rebranding of our software tools and now have an even more professional software workbench for medicinal and computational chemists. This is complemented by our growing Consulting Services division, including the first full year of operation of our innovative CompChem-on-Demand service.”
“The breadth and range of consulting projects that Cresset undertakes demonstrates the power and scope of Cresset’s underlying patented technology,” says Dr Martin Slater, Head of Consulting. “We have completed consulting projects this year on research areas as diverse as virtual screening against a novel rheumatoid arthritis target and discovery of new sweeteners for a global drinks manufacturer.”
Dr Scoffin adds, “As companies increasingly choose to outsource computational chemistry in order to take advantage of just-in-time expertise, we expect Cresset to continue to enjoy outstanding growth throughout and beyond 2013.”
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE